VSYS yields 1000000.00% · ABBV yields 3.06%● Live data
📍 VSYS pulled ahead of the other in Year 1
Combined, VSYS + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of VSYS + ABBV for your $10,000?
Viscount Systems, Inc., through its subsidiary, Viscount Communication and Control Systems Inc., designs, manufactures, and sells access control and security products in North America. It offers intercom and physical access control systems, and emergency communications systems for various applications, including condominium/apartment building access and intercom; residential intercom; gated home/community access and intercom; seniors/government housing access, tracking, and intercom; elevator access and tracking; garage or perimeter gate control; and emergency communications. The company's principal product is the Enterphone intercom and access control system, a patented building entry control system that uses a building's internal phone wiring to allow access control for tenants, and intercom and access control between visitors and tenants. It also manufactures electronic entry access panels that can operate using the Enterphone system or dial-up telephone company lines. In addition, the company offers Enterphone iQ, a solution based on its MESH technology; MESH, a software-based building management system; Freedom, an Internet technology platform; and Liberty, a derivation of the Freedom for the smaller sized system access control market. Viscount Systems, Inc. was founded in 1969 and is headquartered in Burnaby, Canada.
Full VSYS Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.